Skip to content
Home/ AIDS, Women, and the Next Generation: Towards a Morally Acceptable Public Policy for HIV Testing
AIDS, Women, and the Next Generation: Towards a Morally Acceptable Public Policy for HIV Testing

AIDS, Women, and the Next Generation: Towards a Morally Acceptable Public Policy for HIV Testing

No customer reviews yet ISBN 9780195065725 Oxford University Press

The proliferation of Acquired Immune Deficiency Syndrome (AIDS) among women and children represents one of the gravest health issues confronting contemporary society. Women, most of childbearing age, now constitute 11 percent of all cases, and the U.S. Public Health Service has projected over 3,000 cases of pediatric AIDS by the end of 1991. In the face of these sobering statistics, experts have been called upon to grapple with a difficult, compelling question: under what conditions, if any, should HIV testing of women and children be required? Also at issue are the surreptitious testing for HIV antibodies as part of routine prenatal and neonatal examinations, and whether such testing should be performed on all women and infants, or only those who belong to groups judged at "high risk". In this unique contribution to the debate about HIV screening and testing, Ruth Faden, Madison Powers, and Gail Geller have assembled perspectives from experts in public health, medicine, law, and ethics. Their wide-ranging treatment examines the history of prenatal and neonatal screening programs; informed consent; legal issues and confidentiality; reproductive decision-making; and numerous other aspects of HIV testing. Alternative policy options for both now and the future are discussed in detail. This volume provides a comprehensive analysis of these pressing medical, public health, legal, ethical, and social issues, and is essential reading for AIDS researchers and clinicians, public health specialists, ethicists, health policymakers and analysts, obstetricians, and pediatricians.

About the author

Product details

BrandOxford University Press
Pub dateOct 10, 1991
ISBN-100195065727
ISBN-139780195065725
LanguageEnglish
Dimensions6.38 × 1.36 × 9.5 in
Weight2 lb
Last updated 2026-08-10 19:24
$59.56
In stock — ships in 24 hours with free tracking
Delivery by Monday, September 14, 2026
Qty
Sign in to Add to Saved list
Free delivery on orders over $35.
15-day returns. Any reason.
Secure checkout. We never store card details.

Readers who bought this also bought

More from Health Policy
See all
Infectious Disease in Aquaculture: Prevention and Control
With an ever increasing demand for seafood that cannot be met by capture fisheries alone, growing pressure is being placed on aquaculture production. However, infectious diseases are a major constraint. Infectious disease in aquaculture: prevention and control brings together a wealth of recent research on this problem and its effective management. <p/>Part one considers the innate and adaptive immune responses seen in fish and shellfish together with the implications of these responses for disease control. The specific immune response of molluscs and crustaceans is considered in depth, along with the role of stress in resistance to infection. Advances in disease diagnostics, veterinary drugs and vaccines are discussed in part two, with quality assurance, the use and effects of antibiotics and anti-parasitic drugs in aquaculture, and developments in vaccination against fish are explored. Part three focuses on the development of specific pathogen-free populations and novel approaches for disease control. Specific pathogen free shrimp stocks, developments in genomics and the use of bacteria and bacteriophages as biological agents for disease control are explored, before the management and use of natural antimicrobial compounds. <p/>With its distinguished editor and expert team of contributors, Infectious disease in aquaculture: prevention and control provides managers of aquaculture facilities and scientists working on disease in aquaculture with a comprehensive and systematic overview of essential research in the prevention and control of infectious disease.
$323.70